公开(公告)号：US12076366B2

公开(公告)日：2024-09-03

申请号：US16920652

申请日：2020-07-03

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Laura M. Hales ,  Daniel B. Hall ,  Christopher So ,  Howard P. Sard ,  Vishnumurthy Hegde

IPC: A61K38/10 ,  A61K9/00 ,  A61K38/22 ,  A61K47/55 ,  A61K47/60

CPC classification number: A61K38/10 ,  A61K9/0019 ,  A61K38/22 ,  A61K47/551 ,  A61K47/60

Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.

公开(公告)号：US09616109B2

公开(公告)日：2017-04-11

申请号：US14919572

申请日：2015-10-21

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Laura M. Hales ,  Daniel B. Hall ,  Howard Sard ,  Vishnumurthy Hegde

IPC: A61K38/28 ,  A61K9/00 ,  A61K47/48 ,  C07K14/62

CPC classification number: A61K38/28 ,  A61K9/0019 ,  A61K47/551 ,  A61K47/60 ,  A61K47/64 ,  C07K14/62

Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.

公开(公告)号：US20180311307A1

公开(公告)日：2018-11-01

申请号：US16034046

申请日：2018-07-12

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Laura M. Hales ,  Daniel B. Hall ,  Christopher So ,  Howard P. Sard ,  Vishnumurthy Hegde

IPC: A61K38/10 ,  A61K47/55 ,  A61K47/60 ,  A61K9/00 ,  A61K38/22

CPC classification number: A61K38/10 ,  A61K9/0019 ,  A61K38/22 ,  A61K47/551 ,  A61K47/60

Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.

公开(公告)号：US20160113993A1

公开(公告)日：2016-04-28

申请号：US14919601

申请日：2015-10-21

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Laura M. Hales ,  Daniel B. Hall ,  Christopher So ,  Howard P. Sard ,  Vishnumurthy Hegde

IPC: A61K38/10 ,  A61K47/48

CPC classification number: A61K38/10 ,  A61K9/0019 ,  A61K38/22 ,  A61K47/551 ,  A61K47/60

Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.

Abstract translation: 本发明提供与apelin蛋白缀合的非激素维生素D，与未缀合形式相比，其导致增加的吸收，生物利用度或循环半衰期。 在一些实施方案中，维生素D靶向基团通过维生素D主链上的第三个碳原子连接到apelin蛋白。

公开(公告)号：US20240139289A1

公开(公告)日：2024-05-02

申请号：US18368347

申请日：2023-09-14

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Daniel B. Hall ,  Rachel Covitz ,  Garry Musso ,  Caroline Hill ,  Ahmet Vakkasoglu ,  Poul Strange ,  Tilmann M. Brotz

IPC: A61K38/29 ,  A61K47/55 ,  A61K47/60

CPC classification number: A61K38/29 ,  A61K47/551 ,  A61K47/60

Abstract: The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.

公开(公告)号：US20220409697A1

公开(公告)日：2022-12-29

申请号：US17769916

申请日：2020-10-19

Applicant: RAMEA LLC ,  Extend Biosciences Inc.

Inventor： Russell J. Barron ,  Tarik Soliman ,  Daniel B. Hall

IPC: A61K38/19 ,  A61K47/55

Abstract: The invention provides non-hormonal Vitamin D conjugated to G-CSF or compounds with G-CSF activity or GM-CSF or compounds having GM-CSF activity singly or in combination that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.

公开(公告)号：US09789197B2

公开(公告)日：2017-10-17

申请号：US14919671

申请日：2015-10-21

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Laura M. Hales ,  Daniel B. Hall ,  Howard P. Sard ,  Vishnumurthy Hegde

IPC: C07H21/04 ,  A61K47/48 ,  A61K31/713 ,  A61K31/00

CPC classification number: A61K47/551 ,  A61K31/00 ,  A61K31/713 ,  A61K47/60

Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.

公开(公告)号：US12233115B2

公开(公告)日：2025-02-25

申请号：US18368347

申请日：2023-09-14

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Daniel B. Hall ,  Rachel Covitz ,  Garry Musso ,  Caroline Hill ,  Ahmet Vakkasoglu ,  Poul Strange ,  Tilmann M. Brotz

IPC: A61K38/29 ,  A61K47/55 ,  A61K47/60

Abstract: The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.

公开(公告)号：US10702574B2

公开(公告)日：2020-07-07

申请号：US15430449

申请日：2017-02-11

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Laura M. Hales ,  Daniel B. Hall ,  Christopher So ,  Howard P. Sard ,  Vishnumurthy Hegde

IPC: A61K38/10 ,  A61K47/60 ,  A61K47/55 ,  A61K9/00 ,  A61K38/22

Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.

公开(公告)号：US20190183966A1

公开(公告)日：2019-06-20

申请号：US16261507

申请日：2019-01-29

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Laura M. Hales ,  Daniel B. Hall ,  Christopher So ,  Howard P. Sard ,  Vishnumurthy Hegde

IPC: A61K38/10 ,  A61K47/55 ,  A61K9/00 ,  A61K38/22 ,  A61K47/60

CPC classification number: A61K38/10 ,  A61K9/0019 ,  A61K38/22 ,  A61K47/551 ,  A61K47/60

Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.